Zynerba Pharmaceuticals Inc. (ZYNE) Stock Price Up 4.1%
Shares of Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) rose 4.1% on Thursday . The company traded as high as $10.19 and last traded at $9.91, with a volume of 143,671 shares trading hands. The stock had previously closed at $9.52.
ZYNE has been the topic of a number of analyst reports. Canaccord Genuity restated a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Monday, April 18th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 3rd. Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $42.00 price objective on shares of Zynerba Pharmaceuticals in a report on Tuesday, July 26th. Six analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $28.58.
The company’s market capitalization is $90.90 million. The firm has a 50-day moving average price of $8.05 and a 200-day moving average price of $8.16.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.18. Equities analysts anticipate that Zynerba Pharmaceuticals Inc. will post ($2.44) EPS for the current year.
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.